07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

PEG-IFN lambda: Phase IIb data

Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.   Product: PEG-IFN lambda (peginterferon lambda) ( PEG-rIL-29)   Business: Infectious   Molecular target: Interleukin-29 (IL-29) (IFNL1)   Description: Pegylated recombinant IL-29   Indication: Treat HBV infection   Endpoint: Proportion of patients...
07:00 , Mar 24, 2014 |  BioCentury  |  Strategy

The price of success

Payers are so far covering the new HCV drugs from Gilead Sciences Inc. and Johnson & Johnson, but they are already looking forward to new drugs expected to hit the market in the next 18...
08:00 , Nov 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Viral infection IL-29 (IFNL1) Studies in patient samples suggest IL-29 could help treat the viral infections...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

PEG-IFN lambda: Interim Phase IIb data

Interim data from 41 treatment-naïve patients with chronic HCV genotype 1 infection in the double-blind, international Phase IIb D-LITE trial showed that 90% (n=37) of patients achieved a protocol defined response (PDR) while receiving once-weekly...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

Asunaprevir: Phase IIb data

Interim data from 41 treatment-naïve patients with chronic HCV genotype 1 infection in the double-blind, international Phase IIb D-LITE trial showed that 90% (n=37) of patients achieved a protocol defined response (PDR) while receiving once-weekly...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

Daclatasvir: Phase IIb data

Interim data from 41 treatment-naïve patients with chronic HCV genotype 1 infection in the double-blind, international Phase IIb D-LITE trial showed that 90% (n=37) of patients achieved a protocol defined response (PDR) while receiving once-weekly...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Clinical News

PEG-IFN lambda: Additional Phase II data

Data from 118 treatment-naïve patients with chronic HCV genotype 2 or 3 infection in the Phase IIb portion of the international Phase II EMERGE trial showed that 65.5%, 75.9% and 60% of patients achieved an...
01:02 , Apr 20, 2012 |  BC Extra  |  Clinical News

Bristol-Myers reports first SVR data for PEG-IFN lambda

Bristol-Myers Squibb Co. (NYSE:BMY) reported sustained virologic response data for 118 treatment-naive patients with chronic HCV genotype 2 or 3 infection treated with PEG-Interferon lambda in the Phase IIb portion of the Phase II EMERGE...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Clinical News

PEG-IFN lambda: Phase IIb data

Data from the Phase IIb portion of the international Phase II EMERGE trial in 526 treatment-naïve patients with chronic HCV infection showed that 120, 180 and 240 µg weekly subcutaneous PEG-interferon lambda plus Copegus...
07:00 , Oct 4, 2010 |  BioCentury  |  Strategy

Times changed

By acquiring ZymoGenetics Inc. for $885 million in cash, Bristol-Myers Squibb Co. will get full ownership of PEG-Interferon lambda in a bet that interferons will remain an essential part of HCV treatment for years to...